Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924521 | 0.94 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL350478 | 0.94 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10246305 | 0.88 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225662 | 0.83 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL24459113 | 0.83 | APOBEC3A (0.41) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL29664779 | 0.81 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2005769 | 0.81 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10318609 | 0.81 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23778552 | 0.81 | HIF1A (0.44) | — | |
| SCHEMBL3591264 | 0.81 | OPRM1 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-114591319-B | Tetrahydropyridopyrimidine derivative and application thereof | 江苏先声药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-114591319-A | Tetrahydropyridopyrimidine derivative and application thereof | 江苏先声药业有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | ANGEX PHARMACEUTICAL, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026936-B2 | Piperidinyl-propanone derivatives | PDK2, PDK3, PDK1 | OPRM1 3740/4885OPRD1 1363/4885OPRK1 850/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRD1 399/4885OPRK1 647/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | OPRM1 3013/4885OPRD1 2700/4885OPRK1 2599/4885 |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | IDO1, IDO2, INMT | OPRM1 3327/4885OPRD1 2816/4885OPRK1 1701/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | OPRM1 3988/4885OPRD1 3361/4885OPRK1 2456/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRD1 399/4885OPRK1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.